RxDoctor Payments Data

Haris Mirza, MD

Infectious Disease · Ocala, FLNPI 1912956335

Payments from drug & device makers

$9,994in general payments, 2019–2025

Across 498 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$2K
  • Viiv Healthcare Company$1K
  • Merck$1K
  • Johnson & Johnson$628
  • Theratechnologies Inc.$525
  • Insmed, Inc.$486
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$9,92399%
  • Education$721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,994 in reported general payments places this provider in the 80th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,702,099
Medicare patients
649
Services billed
357,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi35$140,384
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5036$128,180
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$72,154
JulucaDolutegravir/Rilpivirine19$70,553
Vancomycin Hcl148$36,942
Daptomycin77$35,615
DovatoDolutegravir Sodium/Lamivudine12$35,149
SantylCollagenase Clostridium Hist.26$29,995
Cefepime Hcl114$16,116
Doxy 100Doxycycline Hyclate32$11,308
CeftriaxoneCeftriaxone Sodium129$8,507
Meropenem21$8,482
Aztreonam20$7,333
Doxycycline Hyclate212$5,841
Ampicillin Trihydrate65$4,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Juluca, Dovato$1,431$246,08666 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$32$128,18036 claims
PfizerOctagam$98$72,15412 claims
Smith+NephewSantyl$321$29,99526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →